NEW
FDA Kava Warnings: How Safe is it?
Hyla Cass, MD
April 2, 2002
The Food and Drug Administration (FDA) is advising
consumers of the potential risk of liver damage associated with
the use of kava-containing dietary supplements. Indigenous to the
islands in the South Pacific, kava (Piper methysticum) has
become one of the top-selling herbs in the U.S., ranking ninth in
retail sales in 2000. Kava's widespread popularity is based on its
well-recognized ability to safely relieve stress, anxiety and tension
sleeplessness, menopausal symptoms and other conditions.
Kava came under the scrutiny of the United States
Food and Drug Administration (FDA) after a number of European reports
that it might cause damage to the liver - including hepatitis, cirrhosis,
and liver failure. German and Swiss health authorities have identified
approximately 30 such cases, including four cases requiring transplantation,
and one death. As a result, regulatory agencies in Germany, Switzerland,
France, Canada, and the United Kingdom, have taken actions ranging
from warning consumers about the potential risks of kava use, to
removing kava-containing products from the marketplace. In the U.S.,
FDA has received several reports of kava-related liver damage, including
a report of a previously healthy young woman who required a liver
transplant. Although the incidence appears to be rare, FDA believes
consumers should be informed of potential risks (see
box below).
The Evidence So Far
Concerned by these reports, a coalition of U.S.
trade associations from the dietary supplement and herbal industry
responded by hiring a highly regarded professional toxicologist
to evaluate the potential relationship between kava consumption
and liver problems. After carefully analyzing the available data,
his final report concluded that, based on the lack of specific clinical
and historical information, "there is no clear evidence that the
liver damage reported in the U.S. and Europe was caused by the consumption
of kava." Additionally the report found that, even in instances
of possible association between kava and liver damage, the cases
appear to have been hypersensitivity or idiosyncratic-based responses.
It also was shown that the vast majority 30 European cases, 21 in
all, involved the concomitant use of hepatotoxic drugs and/or alcohol.
The report concluded that the medical community
and the general public should be informed that kava should not be
taken in conjunction with prescription drugs associated with liver
damage, excessive alcohol consumption, and by those with pre-existing
liver disease or with compromised liver function. At the same time,
attention was drawn to two specific cases of consumption of very
large quantities of kava, that, from a toxicological perspective,
provide some evidence that kava itself is not a direct hepatotoxin,
even in extremely high concentrations."
Research Results Show High Level of Safety
Prior research bears out his conclusions. Kava
has a long tradition of safe use in the South Pacific as a ceremonial
and medicinal drink, often at considerably higher doses than those
used in Europe. In fact, the safety and toxicity of kava has been
extensively studied in recent years, with very few reported liver
toxic effects.
The longest running study conducted to date, with
101 people for 6 months taking 70 mg 3 times a day had negligible
side effects, and in fact, the placebo group reported more side
effects than those taking the kava. The researcher concluded that,
in contrast to both benzodiazapines and antidepressants, kava possesses
an excellent side-effect profile.
The safe and effective benefits of kava to relieve
symptoms of anxiety were also supported in a meta-analysis, a systematic
statistical review of seven human clinical trials published in 2000
in the Journal of Clinical Psychopharmacology, and again in a similar
critical review in 2001. The reviews did not find significant adverse
effects related to liver toxicity. In addition, a recent clinical
study by Professor Jonathan Davidson and Dr. Kathryn Connor from
Duke University, showed no liver abnormalities or other significant
side effects.
In 1990 the German government's Commission E -
a commissioned panel of experts in the fields of medicine and pharmacy
- evaluated the scientific and medical literature. Their conclusion
was that kava should be approved as a nonprescription medicine for
"nervous anxiety, stress, and restlessness."
Kava Safer Than Conventional and OTC Drugs
The large number of published safety and toxicity
studies clearly indicate that kava is far safer - and less hepatotoxic
- than conventional pharmaceutical anti-anxiety and antidepressant
prescription drugs.
For example, one is far likelier to suffer liver
damage from the prescription anti-anxiety drug, Valium, which also
carries the risk of other serious side effects, such as addiction
and concomitant withdrawal symptoms that can include seizures.
Additionally, the leading single cause of liver
failure in Western countries is overdose of the common pain medication,
acetominophen (Tylenol). In fact, acetominophen overdose patients
are placed in a special category as candidates for liver transplant
because the speed of liver damage requires immediate treatment.
Despite the fact that prescription and over-the-counter
drugs such Valium and acetominophen are taken by millions daily,
there is very little public question as to their safety - and virtual
no major adverse publicity.
Conclusion While a more thorough investigation
is needed before drawing any final conclusions about kava's potential
toxicity, this issue underscores the importance - and the vulnerability
- of the liver. The liver is the body's principle chemical factory,
responsible for a complex array of duties ranging from detoxification
of ingested chemicals and filtering waste products to metabolizing
nutrients for energy and storing excess energy for later conversion
into fuel.
Ironically, while the topic here is the potential
hepatotoxicity of an herb, the plant kingdom provides us with such
life-saving liver-protective herbs as milk thistle. In fact, in
my clinical practice I include milk thistle in the regimen of clients
who have been exposed to liver-damaging drugs, both to protect the
liver and to restore its vital function.
The current situation does point out that the liver
is affected by many substances, including prescription and non-
prescription drugs, as well as alcohol, which is a major cause of
liver damage.
We must be aware that herbs are potent medicines,
to be treated with the appropriate respect regarding potential interactions
and toxicity, including to the liver. That being said, kava's margin
of safety far surpasses that of its pharmaceutical equivalent. Nothing
would be gained by previously satisfied consumers of kava, out of
fear of these potential side effects, switching to a more toxic
prescription medication, such as a benzodiazepine, in the mistaken
belief that they were making a safer choice.
Kava Recommendations
In the interest of safety, until more details are
known, the FDA recommends, and we concur, that consumers
of kava consider the following:
- Kava should not be used by anyone who has any
liver problems, or by anyone who is taking any drug
product with known adverse effects on the liver, or
anyone who is a regular consumer of alcohol.
- Consumers should discontinue use if symptoms
of jaundice (e.g., dark urine, yellowing of the eyes)
occur.
- Consumers should consult their primary healthcare
provider if they have a history of liver problems
or suspect possible liver problems before using kava
or continuing its use.
- Since the reports so far are associated with
chronic use, we suggest that kava not be taken on
a daily basis for more that 3 months, which is in
keeping with the German Commission E's recommendation.
- Given that adverse reactions have been reported
in Germany, where higher doses above recommended levels
are routinely prescribed, we further recommend a maximum
intake of 125 mg kavalactones per tablet or capsule,
3g of dried rhizome per teabag, and 250 mg kavalactones
maximum daily dose for all forms.
|
|
|